In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cellular and Infection Microbiology"
DOI: 10.3389/fcimb.2022.906563
Abstract: Background Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective The aim of this study was to assess the in vitro activity of… read more here.
Keywords: ibrexafungerp scy; ibrexafungerp; candida; blood isolates ... See more keywords
The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Fungi"
DOI: 10.3390/jof8050440
Abstract: Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell transplantation (HSCT). Despite relatively high incidence, diagnosis and treatment remain a challenge due to… read more here.
Keywords: ibrexafungerp; feasibility; hematological malignancies; fungal infections ... See more keywords